Not medical advice. A record of published research and our assessments of it. The limits

Trials

Registered trials that could change what is known. Status and completion dates are read from ClinicalTrials.gov and every change is kept, including dates that slip.

01All trials

304 trials, those enrolling people without obesity first

Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie DietNCT04122716 · Unknown · Phase 4 · 215 participants · Primary completion 2019-11 · BMI 32 or higher
Effects of Liraglutide in Chronic Obstructive Pulmonary DiseaseNCT03466021 · Completed · Phase 4 · 40 participants · Primary completion 2020-05-31 · BMI 27 or higher
population of special interest (non-obese / healthy / non-diabetic)
Dulaglutide and Insulin MicrosecretiON in Type 1 DiabetesNCT03668470 · Completed · Phase 2 · 45 participants · Primary completion 2021-02-03
population of special interest (non-obese / healthy / non-diabetic)
Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male VolunteersNCT03835013 · Completed · NA · 26 participants · Primary completion 2021-11-01 · BMI 18 or higher
non-weight indication: cardiovascular
Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial DiseaseNCT04146155 · Unknown · Phase 4 · 200 participants · Primary completion 2021-12-31
non-weight indication: cardiovascular
Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.NCT04969627 · Completed · Phase 4 · 60 participants · Primary completion 2022-01-04 · BMI 24 or higher
non-weight indication: endocrine, other_emerging
GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)NCT04876027 · Completed · Phase 4 · 68 participants · Primary completion 2022-04-30 · BMI 24 or higher
non-weight indication: endocrine, other_emerging
Study of the Cardiometabolic Effects of Obesity PharmacotherapyNCT04575194 · Unknown · Phase 4 · 40 participants · Primary completion 2022-09-30 · BMI 27 or higher
non-weight indication: cardiovascular
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee OsteoarthritisNCT05064735 · Completed · Results posted · Phase 3 · 407 participants · Primary completion 2023-07-24 · BMI 30 or higher
non-weight indication: osteoarthritis
Diabetes Remote Intervention to improVe Use of Evidence-based MedicationsNCT06046560 · Completed · Results posted · Phase 4 · 200 participants · Primary completion 2023-07-25
non-weight indication: cardiovascular
Semaglutide Use in Elderly Obese PatientsNCT05302596 · Completed · Results posted · Phase 2 · 16 participants · Primary completion 2023-10-23 · BMI 30 or higher
non-weight indication: lean_mass, aging
The Effect of Lixisenatide on the Effect of Pituitary HormonesNCT05804513 · Unknown · Phase 4 · 10 participants · Primary completion 2023-10-31
non-weight indication: endocrine
Semaglutide for Alcohol Use DisorderNCT05520775 · Completed · Results posted · Phase 2 · 48 participants · Primary completion 2024-04-12
non-weight indication: addiction
Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)NCT04897802 · Completed · Phase 4 · 42 participants · Primary completion 2024-04-30
non-weight indication: endocrine
Effects of Semaglutide in HIV-Associated LipohypertrophyNCT04019197 · Active not recruiting · Results posted · Phase 2 · 108 participants · Primary completion 2024-04-30
non-weight indication: other_emerging
Effects of Semaglutide on Nicotine IntakeNCT05530577 · Completed · Results posted · Phase 2 · 24 participants · Primary completion 2024-05-13
non-weight indication: addiction
Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2DNCT05140694 · Unknown · Phase 4 · 135 participants · Primary completion 2024-06-30 · BMI 23 or higher
non-weight indication: liver
Liraglutide Effects on Epicardial Fat Inflammatory GenesNCT03260881 · Completed · Results posted · Phase 4 · 38 participants · Primary completion 2024-09-05 · BMI 10 or higher
non-weight indication: inflammation, cardiovascular
Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 AnalogueNCT05751720 · Unknown · Phase 1, Phase 2 · 30 participants · Primary completion 2024-10 · BMI 19 or higher
non-weight indication: liver, addiction
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)NCT04971785 · Completed · Results posted · Phase 2 · 457 participants · Primary completion 2024-11-12 · BMI 23 or higher
non-weight indication: liver, addiction
Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolusNCT06057077 · Unknown · Phase 1, Phase 2 · 120 participants · Primary completion 2024-12-31
population of special interest (non-obese / healthy / non-diabetic)
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or ObeseNCT06445075 · Completed · Phase 2 · 102 participants · Primary completion 2025-03-04
Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal FunctionNCT06608433 · Completed · NA · 22 participants · Primary completion 2025-10-31
non-weight indication: kidney, endocrine
Exenatide for Smoking Cessation and Prevention of Weight GainNCT05610800 · Completed · Phase 2 · 140 participants · Primary completion 2025-11-07
non-weight indication: addiction
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or OverweightNCT06588296 · Completed · Phase 3 · 279 participants · Primary completion 2025-11-18 · BMI 27 or higher
non-weight indication: rheumatologic
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 DiabetesNCT05313529 · Completed · NA · 396 participants · Primary completion 2025-12-31 · BMI 19 or higher
non-weight indication: cognition
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightNCT06588283 · Completed · Phase 3 · 281 participants · Primary completion 2026-01-08 · BMI 27 or higher
non-weight indication: rheumatologic
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660 · Completed · Phase 3 · 537 participants · Primary completion 2026-01-22 · BMI 23 or higher
population of special interest (non-obese / healthy / non-diabetic)
GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 DiabetesNCT06630585 · Recruiting · Phase 3 · 42 participants · Primary completion 2026-06 · BMI 23 or higher
population of special interest (non-obese / healthy / non-diabetic)
Semaglutide for Post-Smoking Cessation Weight ManagementNCT06173778 · Recruiting · Phase 2 · 197 participants · Primary completion 2026-07-01 · BMI 27 or higher
non-weight indication: addiction
Semaglutide for Helping Opioid RecoveryNCT06639464 · Recruiting · Phase 2 · 46 participants · Primary completion 2026-08-31
non-weight indication: addiction
Semaglutide in Auto-HSCTNCT06449625 · Not yet recruiting · Phase 2 · 40 participants · Primary completion 2026-12-31 · BMI 18 or higher
non-weight indication: inflammation
A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 DiabetesNCT06894784 · Recruiting · Phase 3 · 36 participants · Primary completion 2027-01 · BMI 23 or higher
population of special interest (non-obese / healthy / non-diabetic)
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot StudiesNCT07483801 · Not yet recruiting · Phase 4 · 112 participants · Primary completion 2027-04 · BMI 30 or higher
non-weight indication: cardiovascular
GLP-1R Agonist Treatment for Opioid Use DisorderNCT06548490 · Recruiting · Phase 2 · 200 participants · Primary completion 2027-04-30 · BMI 18 or higher
non-weight indication: addiction
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)NCT03884075 · Recruiting · Phase 2 · 104 participants · Primary completion 2027-09-03
non-weight indication: liver, addiction
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With ObesityNCT07218445 · Recruiting · Phase 4 · 40 participants · Primary completion 2027-09-18 · BMI 27 or higher
non-weight indication: aging
Albuminuria Reduction Study With Survodutide Treatment in Kidney DiseaseNCT07206290 · Not yet recruiting · Phase 2 · 120 participants · Primary completion 2027-11-30 · BMI 21 or higher
non-weight indication: kidney
Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or TirzepatideNCT06657209 · Recruiting · Phase 4 · 104 participants · Primary completion 2027-12-15
population of special interest (non-obese / healthy / non-diabetic)
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityNCT07657676 · Not yet recruiting · Phase 4 · 116 participants · Primary completion 2027-12-31 · BMI 24 or higher
non-weight indication: cardiovascular
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With SemaglutideNCT07713992 · Not yet recruiting · NA · 72 participants · Primary completion 2027-12-31 · BMI 24 or higher
non-weight indication: liver, addiction
Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 DiabetesNCT07558863 · Recruiting · Phase 4 · 60 participants · Primary completion 2028-03-30 · BMI 24 or higher
non-weight indication: cardiovascular
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086 · Recruiting · Phase 3 · 350 participants · Primary completion 2028-04 · BMI 27 or higher
non-weight indication: rheumatologic
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099 · Recruiting · Phase 3 · 290 participants · Primary completion 2028-05 · BMI 27 or higher
non-weight indication: rheumatologic
Tirzepatide in the Treatment of Cannabis Use DisorderNCT07671248 · Not yet recruiting · Phase 3 · 15 participants · Primary completion 2028-07-31 · BMI 22 or higher
non-weight indication: addiction
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)NCT07718126 · Not yet recruiting · Phase 2, Phase 3 · 60 participants · Primary completion 2028-08-31 · BMI 24 or higher
non-weight indication: liver
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic NephropathyNCT07775846 · Not yet recruiting · Phase 4 · 820 participants · Primary completion 2029-02-28 · BMI 24 or higher
non-weight indication: kidney
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)NCT07218354 · Recruiting · Phase 3 · 622 participants · Primary completion 2029-03-31
non-weight indication: addiction
Fibrosis Lessens After Metabolic SurgeryNCT06374875 · Recruiting · Phase 4 · 120 participants · Primary completion 2029-05-31 · BMI 35 or higher
non-weight indication: liver, addiction
GLP-1 RA for Stage 1 Type 1 DiabetesNCT07430332 · Not yet recruiting · Phase 2 · 15 participants · Primary completion 2029-06-01
population of special interest (non-obese / healthy / non-diabetic)
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial CancerNCT07781150 · Not yet recruiting · Phase 2 · 128 participants · Primary completion 2029-06-30 · BMI 24 or higher
non-weight indication: cancer
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesNCT06082063 · Recruiting · Phase 3 · 2000 participants · Primary completion 2029-07-01 · BMI 10 or higher
non-weight indication: cardiovascular, kidney
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)NCT07083154 · Recruiting · Phase 3 · 420 participants · Primary completion 2029-08-01 · BMI 20 or higher
non-weight indication: cognition, dementia, alzheimers
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIVNCT07221214 · Recruiting · Phase 2 · 200 participants · Primary completion 2029-10-31 · BMI 23 or higher
non-weight indication: cardiovascular, addiction, other_emerging
Focusing on the Menopausal Transition to Improve Mid-Life Women's HealthNCT06975111 · Recruiting · Phase 2, Phase 3 · 200 participants · Primary completion 2029-10-31
non-weight indication: cardiovascular, aging
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic SyndromeNCT07770282 · Not yet recruiting · Phase 3 · 600 participants · Primary completion 2030-07-30
non-weight indication: cardiovascular, psychiatric
Research of Intensive Metabolic Intervention Before Pregnancy in PCOSNCT03383068 · Unknown · Phase 4 · 160 participants · Primary completion 2018-12-31
non-weight indication: endocrine, other_emerging
Evaluating Liraglutide in Alzheimer's DiseaseNCT01843075 · Unknown · Phase 2 · 204 participants · Primary completion 2019-12
The Use of Liraglutide in Brain DeathNCT03672812 · Completed · Phase 3 · 50 participants · Primary completion 2019-12-10
non-weight indication: inflammation
Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver DiseaseNCT03590626 · Completed · NA · 60 participants · Primary completion 2020-01-14
non-weight indication: liver, addiction
The Gut Microbiome in Women With Polycystic Ovary SyndromeNCT03642600 · Completed · Phase 4 · 21 participants · Primary completion 2020-02-01 · BMI 27 or higher
non-weight indication: endocrine, other_emerging
Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS PatientsNCT04029272 · Unknown · Phase 4 · 80 participants · Primary completion 2020-02-28 · BMI 25 or higher
non-weight indication: endocrine, other_emerging
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)NCT03987074 · Completed · Results posted · Phase 2 · 109 participants · Primary completion 2020-07-13 · BMI 60 or higher
non-weight indication: liver, addiction
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular RiskNCT03730662 · Completed · Results posted · Phase 3 · 2002 participants · Primary completion 2021-01-22 · BMI 25 or higher
non-weight indication: cardiovascular
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOSNCT03480022 · Completed · Results posted · Phase 3 · 88 participants · Primary completion 2021-02-22 · BMI 27 or higher
non-weight indication: endocrine, other_emerging
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's DiseaseNCT03439943 · Completed · Phase 2 · 156 participants · Primary completion 2021-04-15
non-weight indication: parkinsons
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver DamageNCT03987451 · Completed · Results posted · Phase 2 · 71 participants · Primary completion 2021-04-22
non-weight indication: liver, addiction
SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's DiseaseNCT04269642 · Unknown · Phase 2 · 99 participants · Primary completion 2021-09-29
non-weight indication: parkinsons
Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic InpatientsNCT05360537 · Completed · Phase 4 · 100 participants · Primary completion 2021-12-01
non-weight indication: inflammation, mortality
Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep ApneaNCT04186494 · Completed · NA · 30 participants · Primary completion 2021-12-31
non-weight indication: sleep
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes MellitusNCT04515849 · Completed · Results posted · Phase 2 · 248 participants · Primary completion 2022-03-08
non-weight indication: kidney
Daily Liraglutide for Nicotine DependenceNCT03712098 · Completed · Results posted · Phase 2 · 40 participants · Primary completion 2022-05-25
non-weight indication: addiction
Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular DiseaseNCT04057261 · Withdrawn · Phase 3 · Primary completion 2022-08
non-weight indication: cardiovascular
Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 DiabetesNCT04307797 · Completed · Phase 4 · 10 participants · Primary completion 2022-10-07 · BMI 25 or higher
non-weight indication: cardiovascular, cerebrovascular
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)NCT04944992 · Completed · Results posted · Phase 2 · 145 participants · Primary completion 2022-10-19 · BMI 25 or higher
non-weight indication: liver, addiction
Semaglutide Treatment On Coronary ProgressionNCT03985384 · Completed · Phase 4 · 140 participants · Primary completion 2022-12-27
non-weight indication: cardiovascular
Effect of Subcutaneous Semaglutide on Kidney Transplant CandidacyNCT04741074 · Terminated · Results posted · Phase 3 · 15 participants · Primary completion 2023-01-31 · BMI 40 or higher
non-weight indication: kidney
Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes MellitusNCT05467514 · Completed · Phase 3 · 35 participants · Primary completion 2023-02-28
non-weight indication: cardiovascular
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)NCT04216589 · Completed · Results posted · Phase 2 · 51 participants · Primary completion 2023-03-16
non-weight indication: cardiovascular, liver, immune, addiction
Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and ObesityNCT04788511 · Completed · Results posted · Phase 3 · 529 participants · Primary completion 2023-04-18
non-weight indication: cardiovascular
Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes PatientsNCT05147896 · Unknown · NA · 100 participants · Primary completion 2023-05-01
non-weight indication: cardiovascular
Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery PatientsNCT03743025 · Terminated · Results posted · Phase 4 · 28 participants · Primary completion 2023-05-02 · BMI 25 or higher
non-weight indication: cardiovascular
Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance ImagingNCT03498001 · Completed · NA · 42 participants · Primary completion 2023-06-06 · BMI 30 or higher
non-weight indication: cardiovascular
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityNCT03574597 · Completed · Results posted · Phase 3 · 17604 participants · Primary completion 2023-06-21
non-weight indication: cardiovascular, cerebrovascular
Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic NephropathyNCT06182891 · Completed · NA · 300 participants · Primary completion 2023-06-30
non-weight indication: kidney
Use of a GLP-1R Agonist to Treat Opioid Use DisorderNCT04199728 · Completed · Results posted · Phase 1, Phase 2 · 27 participants · Primary completion 2023-09-13
non-weight indication: addiction, ophthalmologic
Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)NCT03648554 · Unknown · Phase 4 · 93 participants · Primary completion 2023-09-30
non-weight indication: liver, addiction
Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" TrialNCT04535960 · Unknown · Phase 2 · 36 participants · Primary completion 2023-10
non-weight indication: cardiovascular
Treating PCOS With Semaglutide vs Active Lifestyle InterventionNCT03919929 · Completed · Results posted · Phase 2, Phase 3 · 60 participants · Primary completion 2023-10-03
non-weight indication: liver, endocrine
Exenatide Treatment in Parkinson's DiseaseNCT04305002 · Unknown · Phase 2 · 60 participants · Primary completion 2023-10-10
non-weight indication: parkinsons
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 DiabetesNCT04916470 · Completed · Phase 3 · 617 participants · Primary completion 2023-10-11
non-weight indication: cardiovascular
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)NCT04771273 · Completed · Results posted · Phase 2 · 295 participants · Primary completion 2023-11-09
non-weight indication: liver, addiction
Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes MellitusNCT03948347 · Unknown · NA · 1708 participants · Primary completion 2023-12
non-weight indication: cerebrovascular
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)NCT04166773 · Completed · Results posted · Phase 2 · 190 participants · Primary completion 2023-12-11 · BMI 27 or higher
non-weight indication: liver, addiction
Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AFNCT06660134 · Completed · NA · 174 participants · Primary completion 2023-12-31 · BMI 25 or higher
non-weight indication: cardiovascular
Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF PatientsNCT04885634 · Withdrawn · Phase 3 · Primary completion 2024-01 · BMI 30 or higher
non-weight indication: cardiovascular
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney DiseaseNCT03819153 · Completed · Results posted · Phase 3 · 3533 participants · Primary completion 2024-01-09
Semaglutide in Nonalcoholic Fatty Liver DiseaseNCT05813249 · Completed · Phase 4 · 180 participants · Primary completion 2024-02-15 · BMI 30 or higher
non-weight indication: liver, addiction
Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's DiseaseNCT04232969 · Completed · Phase 3 · 194 participants · Primary completion 2024-02-24
non-weight indication: parkinsons
Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 DiabetesNCT05597202 · Unknown · Phase 4 · 22 participants · Primary completion 2024-03
non-weight indication: inflammation, cardiovascular
Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes MellitusNCT06475586 · Completed · Phase 4 · 30 participants · Primary completion 2024-03-01
non-weight indication: inflammation, rheumatologic
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep ApneaNCT05412004 · Completed · Results posted · Phase 3 · 469 participants · Primary completion 2024-03-12 · BMI 30 or higher
non-weight indication: sleep
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related PrediabetesNCT05193578 · Completed · Phase 2 · 154 participants · Primary completion 2024-03-18 · BMI 27 or higher
non-weight indication: psychiatric
Adiponectin in Patients With Metabolic DisordersNCT07539584 · Completed · NA · 130 participants · Primary completion 2024-04-08
non-weight indication: liver
Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney DiseaseNCT05254418 · Completed · Results posted · Phase 2 · 7 participants · Primary completion 2024-05-01
non-weight indication: kidney, muscle
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older AdultsNCT05786521 · Completed · Results posted · Phase 4 · 20 participants · Primary completion 2024-05-20 · BMI 27 or higher
non-weight indication: lean_mass, aging
SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without DiabetesNCT04889183 · Completed · Phase 3 · 125 participants · Primary completion 2024-05-28
non-weight indication: kidney
Diabetes Islet Preservation Immune TreatmentNCT02586831 · Withdrawn · Phase 1, Phase 2 · Primary completion 2024-06-01
non-weight indication: inflammation, rheumatologic, immune
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT TrialNCT04847557 · Completed · Results posted · Phase 3 · 731 participants · Primary completion 2024-07-02 · BMI 30 or higher
non-weight indication: cardiovascular
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's DiseaseNCT05891496 · Completed · Results posted · Phase 3 · 23 participants · Primary completion 2024-08-19
non-weight indication: inflammation, alzheimers, immune
A Heart Disease Study of Semaglutide in Patients With Type 2 DiabetesNCT03914326 · Completed · Results posted · Phase 3 · 9651 participants · Primary completion 2024-08-23
non-weight indication: cardiovascular, cerebrovascular
Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot StudyNCT05897372 · Terminated · Phase 2 · 1 participants · Primary completion 2024-09-23
non-weight indication: kidney
Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)NCT04979130 · Completed · Phase 4 · 69 participants · Primary completion 2024-10-16 · BMI 28 or higher
non-weight indication: inflammation
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion TherapiesNCT05920889 · Completed · Phase 2 · 140 participants · Primary completion 2024-10-25
non-weight indication: cerebrovascular
Basal Plus GLP1-ra on Glycemic Variability in CKDNCT05218915 · Completed · Phase 4 · 95 participants · Primary completion 2024-10-30
non-weight indication: kidney
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver DiseaseNCT06501326 · Unknown · Phase 4 · 102 participants · Primary completion 2024-10-31
non-weight indication: liver, addiction
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)NCT04865770 · Completed · Results posted · Phase 3 · 106 participants · Primary completion 2024-11-21
non-weight indication: inflammation, kidney
Semaglutide and Vascular RegenerationNCT05870462 · Unknown · Phase 4 · 100 participants · Primary completion 2024-12 · BMI 30 or higher
non-weight indication: cardiovascular
Effect Of Semaglutide In Coronary Atheroma PlaqueNCT05071417 · Unknown · Phase 3 · 120 participants · Primary completion 2024-12
non-weight indication: cardiovascular
Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension TreatmentNCT06361823 · Unknown · Phase 3 · 74 participants · Primary completion 2024-12-01
non-weight indication: cardiovascular, other_emerging
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)NCT05016882 · Completed · Phase 2 · 698 participants · Primary completion 2024-12-17
non-weight indication: liver, addiction
Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive DisorderNCT04466345 · Completed · Phase 2 · 72 participants · Primary completion 2024-12-27 · BMI 25 or higher
non-weight indication: cognition, psychiatric
GLP1R in Parkinson's DiseaseNCT03659682 · Unknown · Phase 2 · 120 participants · Primary completion 2024-12-31
non-weight indication: inflammation, parkinsons, neuroinflammation
Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary SyndromeNCT05702905 · Unknown · Phase 4 · 75 participants · Primary completion 2024-12-31 · BMI 28 or higher
non-weight indication: endocrine, other_emerging
The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial PressureNCT06027567 · Completed · Phase 4 · 38 participants · Primary completion 2025-01-28 · BMI 27 or higher
non-weight indication: cardiovascular, cancer, other_emerging
Combined Active Treatment in Type 2 Diabetes With NASHNCT04639414 · Completed · Phase 4 · 192 participants · Primary completion 2025-01-31
non-weight indication: liver, addiction
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes MellitusNCT05779644 · Unknown · NA · 300 participants · Primary completion 2025-02-23 · BMI 85 or higher
non-weight indication: liver, addiction
Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DMNCT06492330 · Completed · NA · 62 participants · Primary completion 2025-02-28
non-weight indication: liver
Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and NephropathyNCT06555146 · Unknown · NA · 15 participants · Primary completion 2025-03
non-weight indication: kidney
LIROH - Liraglutide for Obesity in HIVNCT06438146 · Unknown · Phase 4 · 40 participants · Primary completion 2025-05 · BMI 30 or higher
non-weight indication: immune, other_emerging
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433 · Completed · Results posted · Phase 3 · 13299 participants · Primary completion 2025-06-12 · BMI 25 or higher
non-weight indication: cardiovascular, cerebrovascular
Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 DrugsNCT07303556 · Active not recruiting · NA · 120 participants · Primary completion 2025-07-01 · BMI 25 or higher
non-weight indication: cardiovascular
Mechanisms of Semaglutide Therapy in Heart Failure PatientsNCT06541509 · Unknown · Phase 1, Phase 2 · 10 participants · Primary completion 2025-07-10
non-weight indication: inflammation, cardiovascular, cancer
Semaglutide Therapy for Alcohol Reduction - TulsaNCT05891587 · Completed · Phase 2 · 80 participants · Primary completion 2025-07-30
non-weight indication: addiction
Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?NCT05895643 · Completed · Phase 2 · 108 participants · Primary completion 2025-07-31
non-weight indication: addiction
Acute Subcutaneous SemaglutidE in Acute Ischemic sTrokeNCT05630586 · Recruiting · Phase 2 · 380 participants · Primary completion 2025-09
non-weight indication: cerebrovascular
Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney DiseaseNCT06344247 · Unknown · NA · 48 participants · Primary completion 2025-09-01 · BMI 85 or higher
non-weight indication: kidney
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)NCT04777409 · Completed · Phase 3 · 1840 participants · Primary completion 2025-09-15
non-weight indication: dementia, alzheimers
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)NCT04777396 · Completed · Phase 3 · 1840 participants · Primary completion 2025-09-16
non-weight indication: dementia, alzheimers
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372 · Completed · Phase 2 · 626 participants · Primary completion 2025-09-24 · BMI 27 or higher
non-weight indication: kidney
Effectiveness of Weight Loss Methods on Lifespan for Metabolic SyndromeNCT06410352 · Recruiting · Phase 4 · 220 participants · Primary completion 2025-09-30 · BMI 27 or higher
non-weight indication: lean_mass
Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)NCT05646199 · Unknown · Phase 2, Phase 3 · 60 participants · Primary completion 2025-09-30
non-weight indication: endocrine, other_emerging
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151 · Completed · Phase 2 · 146 participants · Primary completion 2025-10-01 · BMI 27 or higher
non-weight indication: kidney
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)NCT06309992 · Completed · Phase 3 · 218 participants · Primary completion 2025-10-09 · BMI 27 or higher
non-weight indication: liver, addiction
Semaglutide in Women With Polycystic Ovary Syndrome and ObesityNCT06896981 · Recruiting · Phase 2, Phase 3 · 30 participants · Primary completion 2025-10-31
non-weight indication: cardiovascular, endocrine, other_emerging
Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)NCT05892432 · Completed · Phase 2 · 50 participants · Primary completion 2025-11-04 · BMI 25 or higher
non-weight indication: addiction, ophthalmologic
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367 · Completed · Phase 3 · 445 participants · Primary completion 2025-11-14 · BMI 27 or higher
non-weight indication: osteoarthritis
Effect of Liraglutide in Obese Women With Polycystic Ovary SyndromeNCT05965908 · Completed · Phase 3 · 183 participants · Primary completion 2025-11-30
non-weight indication: endocrine, other_emerging
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCTNCT05708859 · Recruiting · Phase 4 · 120 participants · Primary completion 2025-12 · BMI 25 or higher
non-weight indication: cardiovascular
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)NCT05877547 · Completed · Phase 2 · 381 participants · Primary completion 2025-12-29
non-weight indication: liver, addiction
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and InfertilityNCT05952882 · Unknown · Phase 3 · 188 participants · Primary completion 2025-12-31 · BMI 27 or higher
non-weight indication: endocrine, other_emerging
Efficacy of Mazdutide for Treating PCOSNCT06519656 · Recruiting · Phase 1, Phase 2 · 50 participants · Primary completion 2025-12-31 · BMI 28 or higher
non-weight indication: endocrine, other_emerging
Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes PatientsNCT06924697 · Enrolling by invitation · NA · 46 participants · Primary completion 2026-01-11
non-weight indication: addiction
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421 · Completed · Phase 3 · 2749 participants · Primary completion 2026-03-16 · BMI 25 or higher
non-weight indication: cardiovascular, cerebrovascular, kidney
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use DisorderNCT06817356 · Completed · Phase 2 · 308 participants · Primary completion 2026-03-19
non-weight indication: addiction
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 DiabetesNCT05780905 · Recruiting · Phase 4 · 50 participants · Primary completion 2026-03-31
non-weight indication: cerebrovascular
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066 · Completed · Phase 3 · 2335 participants · Primary completion 2026-04-06 · BMI 30 or higher
non-weight indication: osteoarthritis, sleep
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045 · Completed · Phase 3 · 1946 participants · Primary completion 2026-04-16 · BMI 35 or higher
non-weight indication: cardiovascular
Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart ValvesNCT07610174 · Completed · Phase 2 · 160 participants · Primary completion 2026-04-29
non-weight indication: cardiovascular
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT06937749 · Recruiting · Phase 2 · 165 participants · Primary completion 2026-04-30 · BMI 25 or higher
non-weight indication: liver
Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)NCT06764056 · Not yet recruiting · NA · 120 participants · Primary completion 2026-05
non-weight indication: liver, nutrition
DUTCH Weight Control in Atrial Fibrillation StudyNCT06184633 · Recruiting · Phase 4 · 280 participants · Primary completion 2026-05-01 · BMI 30 or higher
non-weight indication: cardiovascular
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · Completed · Phase 3 · 5531 participants · Primary completion 2026-06-01 · BMI 27 or higher
non-weight indication: cardiovascular, cerebrovascular, kidney
Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIVNCT06935838 · Completed · Phase 2 · 12 participants · Primary completion 2026-06-02 · BMI 27 or higher
non-weight indication: inflammation, other_emerging
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079 · Completed · Phase 3 · 1152 participants · Primary completion 2026-06-16
non-weight indication: sleep
The Impact of Semaglutide Compared to Energy Restriction on Type 2 DiabetesNCT07272343 · Recruiting · Phase 4 · 100 participants · Primary completion 2026-06-30 · BMI 25 or higher
non-weight indication: liver
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05536804 · Completed · Phase 2 · 134 participants · Primary completion 2026-07-06 · BMI 27 or higher
non-weight indication: kidney
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection FractionNCT05371496 · Completed · Phase 4 · 81 participants · Primary completion 2026-07-17 · BMI 30 or higher
non-weight indication: cardiovascular
Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation TherapyNCT06908694 · Recruiting · Phase 4 · 20 participants · Primary completion 2026-07-31
non-weight indication: cardiovascular, cancer
Effect of Semaglutide in Patients With Psoriasis and ObesityNCT06937060 · Recruiting · Phase 3 · 14 participants · Primary completion 2026-07-31
non-weight indication: rheumatologic
Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)NCT07295223 · Recruiting · Phase 3 · 44 participants · Primary completion 2026-08
non-weight indication: inflammation, cardiovascular
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver TransplantNCT05424003 · Recruiting · Phase 2 · 50 participants · Primary completion 2026-08-01
non-weight indication: liver
Tirzepatide for Alcohol Use DisorderNCT06994338 · Recruiting · Phase 2 · 42 participants · Primary completion 2026-08-31
non-weight indication: addiction
Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)NCT05254314 · Active not recruiting · Phase 2 · 100 participants · Primary completion 2026-09 · BMI 27 or higher
non-weight indication: other_emerging
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityNCT06862908 · Recruiting · Phase 2 · 141 participants · Primary completion 2026-09-24 · BMI 28 or higher
non-weight indication: cardiovascular
Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2NCT06396416 · Recruiting · Phase 4 · 60 participants · Primary completion 2026-09-30
non-weight indication: kidney
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled TrialNCT07111494 · Recruiting · Phase 4 · 22 participants · Primary completion 2026-10-15
non-weight indication: rheumatologic, nutrition
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045 · Active not recruiting · Phase 3 · 600 participants · Primary completion 2026-11 · BMI 27 or higher
non-weight indication: sleep
Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility StudyNCT06954090 · Enrolling by invitation · Phase 4 · 50 participants · Primary completion 2026-11-30
non-weight indication: cardiovascular, kidney
Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DMNCT07570810 · Not yet recruiting · NA · 30 participants · Primary completion 2026-11-30
non-weight indication: liver, addiction
Free Fatty Acid Effects In Type 2 DiabetesNCT07677995 · Enrolling by invitation · NA · 60 participants · Primary completion 2026-12
non-weight indication: cardiovascular
Semaglutide vs SitagliptinNCT05195944 · Enrolling by invitation · Phase 4 · 58 participants · Primary completion 2026-12
non-weight indication: liver, addiction
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver DiseaseNCT05067621 · Active not recruiting · Phase 2 · 60 participants · Primary completion 2026-12 · BMI 85 or higher
non-weight indication: liver, addiction
Semaglutide for Smoking Cessation in Patients With DiabetesNCT07059377 · Recruiting · Phase 3 · 100 participants · Primary completion 2026-12
non-weight indication: addiction
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal WomenNCT07057310 · Enrolling by invitation · Phase 4 · 30 participants · Primary completion 2026-12-31 · BMI 30 or higher
non-weight indication: aging
Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)NCT06959784 · Enrolling by invitation · Phase 4 · 142 participants · Primary completion 2026-12-31
non-weight indication: cardiovascular, cerebrovascular
TIRzepatide for the Treatment of Obesity in Patients With Atrial FibrillationNCT06802081 · Recruiting · Phase 2 · 100 participants · Primary completion 2026-12-31 · BMI 27 or higher
non-weight indication: cardiovascular
Liraglutide Effect in Atrial FibrillationNCT03856632 · Active not recruiting · Phase 4 · 60 participants · Primary completion 2026-12-31 · BMI 27 or higher
non-weight indication: cardiovascular
The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic NeuropathyNCT06461377 · Recruiting · Phase 4 · 50 participants · Primary completion 2026-12-31
non-weight indication: cardiovascular
Sit Less, Interact and Move More (SLIMM) 2 StudyNCT05173714 · Recruiting · Phase 2 · 156 participants · Primary completion 2026-12-31
non-weight indication: kidney
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DMNCT06005012 · Active not recruiting · Phase 2 · 120 participants · Primary completion 2026-12-31 · BMI 27 or higher
non-weight indication: liver, addiction
GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver DiseaseNCT06546384 · Not yet recruiting · NA · 64 participants · Primary completion 2026-12-31 · BMI 28 or higher
non-weight indication: liver, addiction
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）NCT06884293 · Active not recruiting · Phase 3 · 479 participants · Primary completion 2026-12-31 · BMI 27 or higher
non-weight indication: liver
Effects of GLP-1RAs on Reproductive Outcomes in PCOS and ObesityNCT06775093 · Not yet recruiting · NA · 392 participants · Primary completion 2026-12-31
non-weight indication: endocrine, other_emerging
Epicardial Cardiac Fat-CT (EPIC-CT)NCT07297589 · Recruiting · Phase 3 · 136 participants · Primary completion 2027-01
non-weight indication: cardiovascular
A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young AdultsNCT07364175 · Recruiting · NA · 60 participants · Primary completion 2027-01 · BMI 27 or higher
non-weight indication: cardiovascular
Semaglutide's Efficacy in Achieving Weight Loss for Those With HIVNCT04174755 · Recruiting · NA · 80 participants · Primary completion 2027-01 · BMI 27 or higher
non-weight indication: immune, other_emerging
Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT StudyNCT07509112 · Not yet recruiting · Phase 2 · 40 participants · Primary completion 2027-01
population of special interest (non-obese / healthy / non-diabetic)
GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic ArthritisNCT07251556 · Not yet recruiting · Phase 4 · 40 participants · Primary completion 2027-01-01 · BMI 25 or higher
non-weight indication: cardiovascular, rheumatologic
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the EndometriumNCT06073184 · Not yet recruiting · Phase 2 · 71 participants · Primary completion 2027-02 · BMI 27 or higher
non-weight indication: cancer
Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in PsoriasisNCT07401992 · Recruiting · Phase 4 · 62 participants · Primary completion 2027-02-28 · BMI 25 or higher
non-weight indication: inflammation, rheumatologic
Study of Tirzepatide for Recovery and Alcohol Use ManagementNCT06727331 · Recruiting · Phase 2 · 20 participants · Primary completion 2027-03-01
non-weight indication: addiction
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) PatientsNCT06774079 · Recruiting · Phase 4 · 24 participants · Primary completion 2027-03-05 · BMI 27 or higher
non-weight indication: inflammation, rheumatologic
GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DMNCT07314684 · Recruiting · Phase 4 · 80 participants · Primary completion 2027-03-08
non-weight indication: inflammation
The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery DiseaseNCT06606821 · Recruiting · Phase 4 · 124 participants · Primary completion 2027-03-20
non-weight indication: cardiovascular
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac SurgeryNCT06361238 · Recruiting · Phase 3 · 260 participants · Primary completion 2027-03-31
non-weight indication: cardiovascular, perioperative
Semaglutide Therapy for Alcohol Reduction (STAR)NCT06015893 · Active not recruiting · Phase 2 · 63 participants · Primary completion 2027-03-31
non-weight indication: addiction
Use of Liraglutide in Children Aged 6 to 12 Years With Severe ObesityNCT07590219 · Active not recruiting · Phase 4 · 30 participants · Primary completion 2027-04
non-weight indication: cardiovascular
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseaseNCT07537088 · Not yet recruiting · Phase 4 · 468 participants · Primary completion 2027-04
non-weight indication: kidney
Effects of Tirzepatide on Muscle and Vascular Health in Obese Older AdultsNCT06811324 · Recruiting · Phase 2 · 20 participants · Primary completion 2027-04-01 · BMI 30 or higher
non-weight indication: cardiovascular, muscle
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With ObesityNCT07293325 · Recruiting · NA · 66 participants · Primary completion 2027-04-02 · BMI 30 or higher
non-weight indication: aging
A Study of CS060380 Tablets in Patients With MASH and ObesityNCT07466017 · Active not recruiting · Phase 2 · 130 participants · Primary completion 2027-04-30 · BMI 30 or higher
non-weight indication: liver
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)NCT05356104 · Recruiting · Phase 2 · 110 participants · Primary completion 2027-05
population of special interest (non-obese / healthy / non-diabetic)
Semaglutide to Reduce Atrial Fibrillation BurdenNCT05209165 · Suspended · Phase 4 · 132 participants · Primary completion 2027-05 · BMI 27 or higher
non-weight indication: cardiovascular
Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)NCT06191848 · Recruiting · Phase 4 · 352 participants · Primary completion 2027-05
non-weight indication: osteoarthritis
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2NCT06931028 · Recruiting · Phase 3 · 260 participants · Primary completion 2027-05-07 · BMI 28 or higher
non-weight indication: sleep
Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)NCT07292519 · Not yet recruiting · Phase 2 · 46 participants · Primary completion 2027-05-15 · BMI 27 or higher
non-weight indication: cognition, addiction
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 DiabetesNCT05822609 · Recruiting · Phase 2 · 60 participants · Primary completion 2027-06
non-weight indication: kidney
Efficacy of a GLP-1/FGF21 Dual Agonist for Treating PCOSNCT07616037 · Recruiting · Phase 2 · 30 participants · Primary completion 2027-06
non-weight indication: endocrine, other_emerging
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With ObesityNCT07738276 · Not yet recruiting · Phase 3 · 60 participants · Primary completion 2027-06-11
non-weight indication: cardiovascular
Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart DiseaseNCT07354880 · Not yet recruiting · Phase 4 · 30 participants · Primary completion 2027-06-30
non-weight indication: cardiovascular
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 SemaglutideNCT07040592 · Recruiting · Phase 2 · 30 participants · Primary completion 2027-06-30
non-weight indication: addiction, other_emerging
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance DialysisNCT07017270 · Recruiting · Phase 4 · 100 participants · Primary completion 2027-07
non-weight indication: kidney
Tirzepatide in MetALDNCT07046819 · Recruiting · Phase 2 · 120 participants · Primary completion 2027-07-30 · BMI 25 or higher
non-weight indication: addiction
Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled TrialNCT07030621 · Not yet recruiting · Phase 3 · 436 participants · Primary completion 2027-07-31
non-weight indication: cerebrovascular
Tirzepatide in Idiopathic Intracranial Hypertension TrialNCT07191873 · Recruiting · Phase 4 · 60 participants · Primary completion 2027-08 · BMI 30 or higher
non-weight indication: cardiovascular, other_emerging
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2NCT06952530 · Active not recruiting · Phase 3 · 487 participants · Primary completion 2027-09
non-weight indication: cardiovascular
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435 · Active not recruiting · Phase 3 · 487 participants · Primary completion 2027-09
non-weight indication: cardiovascular
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422 · Active not recruiting · Phase 3 · 974 participants · Primary completion 2027-09 · BMI 25 or higher
non-weight indication: cardiovascular
DIALYSIS-TIR StudyNCT06042153 · Active not recruiting · Phase 4 · 43 participants · Primary completion 2027-09
non-weight indication: kidney
Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)NCT07756359 · Not yet recruiting · Phase 4 · 20 participants · Primary completion 2027-09
non-weight indication: inflammation
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 · Active not recruiting · Phase 3 · 7101 participants · Primary completion 2027-09-01
non-weight indication: cardiovascular, cerebrovascular
Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With SemaglutideNCT06497595 · Recruiting · NA · 60 participants · Primary completion 2027-09-30 · BMI 27 or higher
non-weight indication: muscle, nutrition
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use DisorderNCT06651177 · Recruiting · Phase 2 · 310 participants · Primary completion 2027-09-30
non-weight indication: addiction
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast CancerNCT06518837 · Recruiting · Phase 2 · 40 participants · Primary completion 2027-09-30
non-weight indication: cancer
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular OutcomesNCT05819138 · Recruiting · Phase 3 · 60 participants · Primary completion 2027-10-01
non-weight indication: cardiovascular
Tirzepatide to Slow Biological AgingNCT07220473 · Recruiting · Phase 2 · 90 participants · Primary completion 2027-11 · BMI 27 or higher
non-weight indication: aging
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)NCT06864026 · Recruiting · Phase 4 · 200 participants · Primary completion 2027-11
non-weight indication: rheumatologic
Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese IndividualsNCT07609160 · Not yet recruiting · NA · 108 participants · Primary completion 2027-11-30 · BMI 27 or higher
non-weight indication: muscle
Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIVNCT07707778 · Enrolling by invitation · Phase 4 · 60 participants · Primary completion 2027-12 · BMI 30 or higher
non-weight indication: aging, other_emerging
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial FibrillationNCT06499857 · Recruiting · Phase 3 · 200 participants · Primary completion 2027-12
non-weight indication: cardiovascular
COMMETS- Combination MCI Metabolic SyndromeNCT06072963 · Recruiting · Phase 2 · 80 participants · Primary completion 2027-12-01
non-weight indication: cognition, alzheimers
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer SurvivorsNCT07257484 · Recruiting · Phase 4 · 30 participants · Primary completion 2027-12-03 · BMI 27 or higher
non-weight indication: cancer
Feasibility of Semaglutide in Advanced Lung DiseaseNCT05746039 · Recruiting · Phase 1, Phase 2 · 8 participants · Primary completion 2027-12-28 · BMI 30 or higher
non-weight indication: cardiovascular
Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart FailureNCT06423599 · Recruiting · Phase 2, Phase 3 · 100 participants · Primary completion 2027-12-30 · BMI 30 or higher
non-weight indication: cardiovascular
Oral Semaglutide in Patients With Alzheimer's DiseaseNCT07200622 · Not yet recruiting · Phase 2 · 60 participants · Primary completion 2027-12-31
non-weight indication: alzheimers
Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial FibrillationNCT07382024 · Not yet recruiting · NA · 200 participants · Primary completion 2027-12-31 · BMI 27 or higher
non-weight indication: cardiovascular
Tirzepatide in the Treatment of Endometrial CancerNCT07605247 · Not yet recruiting · Phase 2 · 30 participants · Primary completion 2028-01 · BMI 27 or higher
non-weight indication: cancer
OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management ProgrammeNCT07779343 · Recruiting · NA · 300 participants · Primary completion 2028-01-23 · BMI 30 or higher
non-weight indication: cardiovascular
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular TreatmentNCT06788626 · Not yet recruiting · Phase 3 · 390 participants · Primary completion 2028-02
non-weight indication: cerebrovascular, neuroinflammation
Combination of Biologic and Anti-obesity Therapies in Psoriatic ArthritisNCT07443956 · Recruiting · NA · 45 participants · Primary completion 2028-02 · BMI 27 or higher
non-weight indication: rheumatologic
Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and ReinitiationNCT07387796 · Recruiting · NA · 40 participants · Primary completion 2028-02
non-weight indication: addiction
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary SyndromeNCT05819853 · Recruiting · Phase 3 · 80 participants · Primary completion 2028-02-01 · BMI 95 or higher
non-weight indication: endocrine, other_emerging
Multi-Site Trial of Tirzepatide for Smoking CessationNCT07602699 · Recruiting · Phase 2 · 300 participants · Primary completion 2028-03
non-weight indication: addiction
Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA TrialNCT07676331 · Not yet recruiting · Phase 2 · 168 participants · Primary completion 2028-03-01
non-weight indication: cancer
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471 · Recruiting · Phase 3 · 800 participants · Primary completion 2028-04
non-weight indication: osteoarthritis
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT TrialNCT07202247 · Recruiting · Phase 2 · 60 participants · Primary completion 2028-04-09 · BMI 30 or higher
non-weight indication: cardiovascular, cancer
Moving Beyond Inflammation as a Therapeutic Target for Crohn's DiseaseNCT06976853 · Recruiting · Phase 2 · 60 participants · Primary completion 2028-05
non-weight indication: inflammation, rheumatologic
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)NCT06857942 · Recruiting · Phase 4 · 200 participants · Primary completion 2028-05
non-weight indication: rheumatologic
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized TrialNCT07734792 · Not yet recruiting · Phase 2, Phase 3 · 430 participants · Primary completion 2028-05-31
non-weight indication: cerebrovascular, mortality
A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney DiseaseNCT07239570 · Recruiting · Phase 4 · 125 participants · Primary completion 2028-06
non-weight indication: kidney
Therapeutic Strategies for Microvascular Dysfunction in Type 1 DiabetesNCT05478707 · Recruiting · Phase 2 · 47 participants · Primary completion 2028-06-30
population of special interest (non-obese / healthy / non-diabetic)
Impact GLP-1 Agonists Following BariatricNCT06132477 · Recruiting · Phase 4 · 150 participants · Primary completion 2028-07
non-weight indication: cardiovascular, sleep
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential MechanismsNCT07073053 · Not yet recruiting · Phase 4 · 60 participants · Primary completion 2028-07-31
non-weight indication: cardiovascular
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use DisorderNCT06939088 · Recruiting · Phase 2 · 108 participants · Primary completion 2028-08-01
non-weight indication: addiction, psychiatric
GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPDNCT07747805 · Not yet recruiting · Phase 2 · 30 participants · Primary completion 2028-08-15 · BMI 27 or higher
non-weight indication: muscle, other_emerging
A Study of Cardiovascular Events iN Diabetes PlusNCT05441267 · Active not recruiting · Phase 4 · 21296 participants · Primary completion 2028-08-17
non-weight indication: cardiovascular
Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal CancerNCT07314528 · Not yet recruiting · Phase 2 · 42 participants · Primary completion 2028-09 · BMI 25 or higher
non-weight indication: inflammation, immune, cancer
Effects of GLP-1RAs on Fertility Outcomes in Obese Women With PCOSNCT07687667 · Not yet recruiting · NA · 406 participants · Primary completion 2028-12
non-weight indication: endocrine, other_emerging
A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or ObeseNCT07326111 · Recruiting · Phase 4 · 198 participants · Primary completion 2028-12 · BMI 27 or higher
non-weight indication: endocrine, other_emerging
Waiting on Atrial Fibrillation Intervention Therapy (WAIT) StudyNCT07275697 · Recruiting · Phase 4 · 200 participants · Primary completion 2028-12-30 · BMI 30 or higher
non-weight indication: cardiovascular, mortality
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac SurgeryNCT06324461 · Recruiting · Phase 4 · 372 participants · Primary completion 2028-12-31
non-weight indication: cardiovascular
Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.NCT07391267 · Not yet recruiting · NA · 90 participants · Primary completion 2028-12-31
non-weight indication: cardiovascular, kidney, liver
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · Active not recruiting · Phase 3 · 10000 participants · Primary completion 2029-02
non-weight indication: cardiovascular, kidney
Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial CancerNCT07078838 · Not yet recruiting · Phase 2 · 40 participants · Primary completion 2029-03
non-weight indication: cancer
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesNCT05390892 · Recruiting · Phase 4 · 6000 participants · Primary completion 2029-03-01
non-weight indication: cardiovascular, kidney
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)NCT07547878 · Not yet recruiting · Phase 4 · 64 participants · Primary completion 2029-03-31
non-weight indication: kidney
Incretin Therapies in Obesity-related HFpEFNCT07554638 · Recruiting · Phase 4 · 50 participants · Primary completion 2029-04 · BMI 30 or higher
non-weight indication: cardiovascular
Semaglutide PrIor to CathEeter Ablation in Patients With Atrial FibrillationNCT07389941 · Not yet recruiting · Phase 4 · 240 participants · Primary completion 2029-04
non-weight indication: cardiovascular
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)NCT04822181 · Active not recruiting · Phase 3 · 1205 participants · Primary completion 2029-04-25
non-weight indication: liver, addiction, mortality
Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 DiabetesNCT07485062 · Not yet recruiting · Phase 4 · 164 participants · Primary completion 2029-05-01
non-weight indication: cognition, aging
Liraglutide Treatment in Obese Infertile PCOS WomenNCT06742710 · Recruiting · Phase 4 · 890 participants · Primary completion 2029-05-30
non-weight indication: endocrine, other_emerging
Body-weight Reduction Effect on Portal Hypertension in Compensated CirrhosisNCT07797101 · Not yet recruiting · NA · 50 participants · Primary completion 2029-05-31 · BMI 26 or higher
non-weight indication: cardiovascular, liver
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's DiseaseNCT07651319 · Recruiting · Phase 1, Phase 2 · 30 participants · Primary completion 2029-06
non-weight indication: inflammation, dementia, alzheimers
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisNCT06632457 · Recruiting · Phase 3 · 1590 participants · Primary completion 2029-06-05 · BMI 25 or higher
non-weight indication: liver, addiction, mortality
Glucagon-Like Peptide-1 Receptor Agonist in ADPKDNCT06582875 · Recruiting · Phase 2 · 126 participants · Primary completion 2029-06-30
non-weight indication: kidney, other_emerging
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579 · Not yet recruiting · Phase 3 · 2001 participants · Primary completion 2029-08
non-weight indication: cardiovascular
Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEFNCT07630454 · Not yet recruiting · Phase 4 · 602 participants · Primary completion 2029-08-01 · BMI 28 or higher
non-weight indication: cardiovascular
Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetesNCT07254572 · Recruiting · Phase 4 · 300 participants · Primary completion 2029-08-01
non-weight indication: cardiovascular
Tirzepatide Weight Loss for MRD+ Early Breast CancerNCT06517212 · Recruiting · Phase 2 · 48 participants · Primary completion 2029-08-31 · BMI 27 or higher
non-weight indication: cancer, mortality
Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection FractionNCT07178145 · Recruiting · Phase 4 · 192 participants · Primary completion 2029-09
non-weight indication: cardiovascular
Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese PatientsNCT07715929 · Not yet recruiting · Phase 4 · 710 participants · Primary completion 2029-09-01 · BMI 28 or higher
non-weight indication: cardiovascular
HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting SemaglutideNCT07760948 · Not yet recruiting · Phase 2 · 90 participants · Primary completion 2029-11-30
non-weight indication: muscle, lean_mass, nutrition
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDNCT07527910 · Recruiting · Phase 2 · 204 participants · Primary completion 2030-03-15 · BMI 30 or higher
non-weight indication: liver
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol SecretionNCT07361874 · Recruiting · NA · 75 participants · Primary completion 2030-05-31 · BMI 27 or higher
non-weight indication: kidney, endocrine
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 · Recruiting · Phase 3 · 4500 participants · Primary completion 2030-08
population of special interest (non-obese / healthy / non-diabetic)
Semaglutide in Patients Undergoing Transcatether Aortic Valve ReplacementNCT07090343 · Not yet recruiting · Phase 3 · 826 participants · Primary completion 2030-09-01 · BMI 30 or higher
non-weight indication: cardiovascular, cerebrovascular
Improved Treatment and Monitoring of Alzheimer's DiseaseNCT07135245 · Not yet recruiting · Phase 2 · 180 participants · Primary completion 2030-09-30
non-weight indication: cognition, alzheimers
Role of GLP1 RA Dulaglutide on Severe Intracranial AtherosclerosisNCT07282041 · Recruiting · Phase 2, Phase 3 · 130 participants · Primary completion 2030-12-01
non-weight indication: cardiovascular, cerebrovascular
SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial CancerNCT07462663 · Not yet recruiting · Phase 4 · 80 participants · Primary completion 2031-04
non-weight indication: cancer
Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase InhibitorsNCT07769047 · Not yet recruiting · Phase 4 · 50 participants · Primary completion 2031-07-30 · BMI 30 or higher
non-weight indication: cardiovascular, cancer
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)NCT07241390 · Recruiting · Phase 3 · 7140 participants · Primary completion 2031-08
non-weight indication: cardiovascular, kidney
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke ThrombectomyNCT07511543 · Not yet recruiting · Phase 3 · 826 participants · Primary completion 2031-09-30
non-weight indication: cerebrovascular
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisNCT06632444 · Recruiting · Phase 3 · 1800 participants · Primary completion 2031-12-27
non-weight indication: liver, addiction, mortality

02Changes

Recent registry changes

No changes recorded.